

All-Scale Manufacturing Solution for mRNA








d All-ScaleFlow[™] platform equipment



Our solution to unleash the potential of mRNA : a continuous end-to-end process platform






IVT Spiral Reactor

Enabling full scalability







15 mL unitary volumes every 20'




d Analytical Platform



Luciferase mRNA	Typical Results
Co-capping IVT mRNA titer (g/L)	11.3
Post IVT Integrity (%)	87

- ✓ In agreement with the USP Pharmacopeia Analytical Guidelines
- ✓ To support and assess platform development
- ✓ For non-GMP mRNA internal production for partners & customers
- ✓ To generate data for modeling activities





Modeling & Digital architecture

Offline Digital Twin

Mechanistic model of the full process

- to speed up optimal process design
- to develop a Model based DoE
- to simulate & understand deviation











mRNAfacturing™ Solution

The agile mRNA-LNP manufacturing solution at all-scale with a GMP-ready process:



Core Platform

- All-ScaleFlow™manufacturing platform
- Reliance package (maintenance)
- Single-Use Spiral



Customized Expert Support

- Digital Tools and Services for Process Development
- Manufacturing Science Services



Other Services

- Exploration package
- Pre-clinical manufacturing services

d Contacts



Christophe Bonneville, CEO Christophe.bonneville@dillico.com +33 6 797 10 999





Flora Binder, Chief Development Officer flora.binder@dillico.com + 33 6 42 17 97 35

www.dillico.com



Emmanuel Gaud, Chief Operation Officer Emmanuel.gaud@dillico.com +33 6 71 48 27 12

